Dextropropoxyphene Kinetics After Single and Repeated Oral Doses in Man

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1985 Jan 1

PMID 4054208

Citations 2

Authors

K Brosen

L F Gram

J Schou

N E Larsen

P Thayssen

Affiliations

Soon will be listed here.

Abstract

The kinetics of dextropropoxyphene (DP) and its main metabolite norpropoxyphene (NP) were studied in 6 healthy male subjects after a single oral dose of 195 mg DP HCl, and during and after 12 daily single oral doses of 195 mg DP HCl. The kinetics varied up to five-fold between individuals after the single dose, the apparent mean elimination half-life (t1/2) was 16 h for DP and 29 h for NP. The mean apparent overall plasma clearance (CL) for DP was 2.61/min. There was no systematic difference in DP clearance between the single and multiple doses, but the accuracy of individual predictions from single to multiple doses was poor, probably because of imprecise determinations of the AUC and t1/2 in the single dose experiments. The individual correlation between single and multiple dose kinetics was good for NP, although the predicted plasma levels during steady state were significantly higher than the observed levels (mean AUCss/AUCsd: 0.81). There was no sign of saturation kinetics on repeated administration. In fact, autoinduction, resulting in significantly lower plasma concentrations after treatment for 1 week was found for NP and was indicated for DP. On discontinuing DP after 12 days of treatment, the apparent mean t1/2 of DP was 23 h and of NP 25 h.

Citing Articles

[Sustained-release dextropropoxyphene.].

Kurz-Muller K, Zenz M Schmerz. 1991; 5(4):233-42.

PMID: 18415177 DOI: 10.1007/BF02527803.

Pharmacokinetics of opioids in liver disease.

Tegeder I, Lotsch J, Geisslinger G Clin Pharmacokinet. 1999; 37(1):17-40.

PMID: 10451781 DOI: 10.2165/00003088-199937010-00002.

References

Wagner J, Welling P, Roth S, Sakmar E, Lee K, Walker J . Plasma concentrations of propoxyphene in man. I. Following oral administration of the drug in solution and capsule forms. Int Z Klin Pharmakol Ther Toxikol. 1972; 5(4):371-80. View

. Cardio-respiratory toxicity of propoxyphene and norpropoxyphene in conscious rabbits. Acta Pharmacol Toxicol (Copenh). 1978; 42(3):171-8. DOI: 10.1111/j.1600-0773.1978.tb02187.x. View

Holland D, Steinberg M . Electrophysiologic properties of propoxyphene and norpropoxyphene in canine cardiac conducting tissues in vitro and in vivo. Toxicol Appl Pharmacol. 1979; 47(1):123-33. DOI: 10.1016/0041-008x(79)90079-6. View

Nickander R, Smits S, Steinberg M . Propoxyphene and norpropoxyphene: pharmacologic and toxic effects in animals. J Pharmacol Exp Ther. 1977; 200(1):245-53. View

Gram L, Schou J, WAY W, Heltberg J, BODIN N . d-Propoxyphene kinetics after single oral and intravenous doses in man. Clin Pharmacol Ther. 1979; 26(4):473-82. DOI: 10.1002/cpt1979264473. View

Gram L, Schou J, Heltberg J, WAY W . d-Propoxyphene single dose kinetics in a subject taking phenobarbital. Acta Pharmacol Toxicol (Copenh). 1980; 46(5):395-7. DOI: 10.1111/j.1600-0773.1980.tb02473.x. View

Thayssen P, Bjerre M, Kragh-Sorensen P, Moller M, Petersen O, Kristensen C . Cardiovascular effect of imipramine and nortriptyline in elderly patients. Psychopharmacology (Berl). 1981; 74(4):360-4. DOI: 10.1007/BF00432748. View

Gram L, Schmidt K, Christensen F, Schou J . D-propoxyphene kinetics in man: significance of a deep third compartment. Eur J Clin Pharmacol. 1984; 26(6):749-52. DOI: 10.1007/BF00541937. View

Inturrisi C, Colburn W, Verebey K, Dayton H, Woody G, OBrien C . Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene. Clin Pharmacol Ther. 1982; 31(2):157-67. DOI: 10.1038/clpt.1982.25. View

10.

Wolen R, Ziege E, Gruber Jr C . Determination of propoxyphene and norpropoxyphene by chemical ionization mass fragmentography. Clin Pharmacol Ther. 1975; 17(1):15-20. DOI: 10.1002/cpt197517115. View

11.

Verebely K, Inturrisi C . Disposition of propoxyphene and norpropoxyphene in man after a single oral dose. Clin Pharmacol Ther. 1974; 15(3):302-9. DOI: 10.1002/cpt1974153302. View

12.

Wolen R, Gruber Jr C, KIPLINGER G, Scholz N . Concentration of propoxyphene in human plasma following oral, intramuscular, and intravenous administration. Toxicol Appl Pharmacol. 1971; 19(3):480-92. DOI: 10.1016/0041-008x(71)90006-8. View

13.

Perrier D, Gibaldi M . Influence of first-pass effect on the systemic availability of propoxyphene. J Clin Pharmacol New Drugs. 1972; 12(11):449-52. DOI: 10.1002/j.1552-4604.1972.tb00245.x. View

14.

FINKLE B, McCloskey K, KIPLINGER G, BENNETT I . A national assessment of propoxyphene in postmortem medicolegal investigation, 1972-1975. J Forensic Sci. 1976; 21(4):706-41. View

15.

Schou J, Angelo H, Dam W, Jensen K, Christensen J . Pharmacokinetics of dextropropoxyphene in acute poisoning. Arch Toxicol Suppl. 1978; (1):343-6. DOI: 10.1007/978-3-642-66896-8_73. View

16.

Peterson G, Hostetler R, Lehman T, Covault H . Acute inhibition of oxidative drug metabolism by propoxyphene (Darvon). Biochem Pharmacol. 1979; 28(11):1783-9. DOI: 10.1016/0006-2952(79)90541-0. View

17.

Wolen R, Gruber Jr C, KIPLINGER G, Scholz N . Concentration of propoxyphene in human plasma following repeated oral doses. Toxicol Appl Pharmacol. 1971; 19(3):493-7. DOI: 10.1016/0041-008x(71)90007-x. View

18.

McMahon R, Ridolfo A, CULP H, Wolen R, Marshall F . The fate of radiocarbon-labeled propoxyphene in rat, dog, and human. Toxicol Appl Pharmacol. 1971; 19(3):427-44. DOI: 10.1016/0041-008x(71)90002-0. View

19.

Gibaldi M, Weintraub H . Some considerations as to the determination and significance of biologic half-life. J Pharm Sci. 1971; 60(4):624-6. DOI: 10.1002/jps.2600600430. View